ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2010
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.BMC urology · 2010Pooled it
- Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.BMJ case reports · 2012Trial
- 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Article
- Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.Cancer management and research · 2015Article
- Bone-targeted therapy in prostate cancer.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2013Review
- Preventing bone complications in advanced prostate cancer.Current oncology (Toronto, Ont.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis and bone fractures are frequently overlooked complications of androgen deprivation therapy in men with nonmetastatic prostate cancer. All such patients should have their bone mineral density (BMD) monitored and be offered preventive measures, such as calcium and vitamin D supplementation; patients with low BMD should be offered treatment. Several agents, including bisphosphonates, are available (although this use is currently off-label), and upcoming treatments, such as denosumab and toremifene, have shown promise in reducing fracture risk in these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.